Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
- Associated Therapies
- -
Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2008-03-26
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 60
- Registration Number
- NCT00644475
- Locations
- 🇮🇹
University of Pavia, Pavia, Italy
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6268
- Registration Number
- NCT00634400
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00634309
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 734
- Registration Number
- NCT00634712
Candesartan Effect in Second Stage Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2010-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT00621153
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Atacand (Candesartan) Real Life Study
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14000
- Registration Number
- NCT00620178
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
The RAS, Fibrinolysis and Cardiopulmonary Bypass
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 111
- Registration Number
- NCT00607672
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸TN Valley Healthcare System, Nashville, Tennessee, United States
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
- Conditions
- Interventions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 53
- Registration Number
- NCT00605072
- Locations
- 🇺🇸
Hebrew SeniorLife, Boston, Massachusetts, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Angiotensin-II Blockade in Mitral Regurgitation
- Conditions
- Interventions
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 60
- Registration Number
- NCT00587470
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
ARIA (Atacand Renoprotection In NephropAthy Pt.)
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT00573430
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.